Prana Biotechnology today reported that it has received a A$2.5 million cash refund under the R&D Tax Incentive Program, a program administered by AusIndustry and the Australian Taxation Office. This payment is part of approximately $5.8 million expected to be received for the 2011-12 and 2012-13 financial years.

Prana Biotechnology is pleased to advise that its Share Purchase Plan (SPP) closed on Friday 26 April 2013 at 5.00 pm (EST) with applications received for 10,370,488 ordinary shares (New Shares).

Prana Biotechnology has unveiled a world first, patient-reported outcomes study for Huntington’s Disease (HD) in a poster presentation at the 17th Annual Congress of Parkinson’s Disease and Movement Disorders being held in Sydney this week.

Prana Biotechnology today welcomed the release of data which indicates its drug candidate PBT434 shows significant disease-modifying capability in multiple animal models of Parkinson’s Disease (PD) with potential utility in a range of movement disorders.

Prana Biotechnology today announced that it has received approval from the Austin Health Human Research Ethics Committee (HREC) to commence a 12-month open label extension study with Alzheimer’s Disease patients participating in Prana’s IMAGINE trial.

Professor Rudy Tanzi has been appointed as Chief Scientific Advisor to the Company. Professor Tanzi is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University, and Director of the Genetics and Aging Research Unit at Massachusetts General Hospital (MGH). Professor Tanzi has been investigating the genetics of neurological disease since 1980 when he participated in the study that led to the first disease gene being identified by genetic analysis (Huntington's Disease).